Upadacitinib effective in treating atopic dermatitis through 76 weeks
In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).
Food Insecurity and the Dangers of Infant Formula Dilution
Saol Therapeutics submits NDA for SL1009 to treat Pyruvate Dehydrogenase Complex Deficiency
If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.
Demystifying Infant Formula
Healthy eyes in a digital world
Colleen Sloan, PA-C, RDN, details how technology can affect eye health in children and identifies which nutrients can help mitigate its effect.
Navigating the holiday health paradox
Mike Hennessy Jr. shares his thoughts on the holiday health paradox.
